搜索
 >  其他蛋白>Rituximab >RIB-Y37

Anti-Rituximab Antibodies (recommended for PK/PD)

表达区间及表达系统(Source)

Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Rituximab F(ab')2.

亚型(Isotype)

IgG1/kappa

特异性(Specificity)

Recognizes Rituximab specifically, no cross reactivity with other humanized antibodies.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. 4-8°C for 12 months in lyophilized state;
  2. -70°C for 3 years under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Anti-Rituximab Antibodies (recommended for PK/PD) (Cat. No. RIB-Y37) SDS-PAGE gel

Anti-Rituximab Antibodies (recommended for PK/PD) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

Biotinylated Human ELISA

Detection of rituximab by bridging ELISA in serum. Immobilized Anti-Rituximab Antibodies (Cat. No. RIB-Y37) at 2 μg/mL, add increasing concentrations of rituximab (10% human serum) and then add Biotinylated Anti-Rituximab Antibodies (Cat. No. RIB-BY35) at 1 μg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 1 ng/mL.

Protocol

Biotinylated Human SPR

Demonstration of the specificity of Anti-Rituximab Antibodies (Cat. No. RIB-Y37) to the rituximab.

Protocol

活性(Bioactivity)-FACS

Biotinylated Human FACS

FACS analysis shows that the binding of rituximab to 293F overexpressing CD20 was inhibited by increasing concentration of Anti-Rituximab Antibodies (Cat. No. RIB-Y37). The concentration of rituximab used is 10 ng/ml. The IC50 is 0.019 μg/ml (Routinely tested).

Protocol

 

背景(Background)

Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids.

 

前沿进展

 
货号/价格

RIB-Y37-100ug / ¥3000

RIB-Y37-1mg (500ug X 2) / ¥19800

开发建议
文档
联系电话:
400-682-2521(全国)
010-57737274(北京)
021-26136428(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
techsupport@acrobiosystems.com

消息提示

请输入您的联系方式,再点击提交!

确定